Urinary incontinence in men: current and developing therapy options.

about

Urinary incontinence in men: current and developing therapy options.

Item

http://www.wikidata.org/entity/Q38708104

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Urinary incontinence in men: current and developing therapy options.

@en

type

Item

label

Urinary incontinence in men: current and developing therapy options.

@en

prefLabel

Urinary incontinence in men: current and developing therapy options.

@en

P1476

Urinary incontinence in men: current and developing therapy options.

@en

P2093

Helena Burden

http://www.w3.org/2001/XMLSchema#string

Paul Abrams

http://www.w3.org/2001/XMLSchema#string

P2860

Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study

Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment

Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.

Pharmacokinetics and safety of solifenacin succinate in healthy young men.

Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence.

Muscarinic receptor antagonists for overactive bladder.

Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.

The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial.

Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review.

Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.

P304

715-726

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2016.1145662

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26800277

http://www.w3.org/2001/XMLSchema#string